Regulatory Strategy and Project Management Across the Development Lifecycle of a Pediatric Growth-Adaptive Vascular Stent System

Pulmonary artery stenosis and coarctation of the aorta in neonates, infants, and young children may require intervention to restore adequate blood flow, a challenge complicated by small vessel size and the certainty of continued patient growth after any implant is placed. A representative balloon-expandable vascular stent designed to address this population illustrates a distinctive regulatory and evidence challenge: a device intended for intentional re-expansion as a pediatric patient grows must demonstrate mechanical integrity not at a single deployed diameter but across an entire expansion range, a requirement conventional vascular stent evidence packages were not originally designed to address. This article uses a device of this kind as a case study to examine its FDA regulatory pathway, evidence requirements, development milestones, and risk management strategy, together with a hypothetical Canadian market entry strategy, and closes with recommendations for regulatory affairs professionals managing growth-adaptive implantable device programs for pediatric populations.Keywords: pediatric vascular stent; growth-adaptive implant; Class III medical device; Premarket Approval; Health Canada Class IV; mechanical fatigue testing; regulatory artificial intelligence